Novartis takes EU lead in oral MS drug market
This article was originally published in Scrip
Executive Summary
Novartis's oral MS drug fingolimod (Gilenya) has been recommended for marketing approval by the EU's Committee for Medicinal Products for Human Use (CHMP) on 20 January, putting it in line to be the first oral MS drug in the EU market dominated by inconvenient injectables. Competing oral drug, Merck KGaA (Serono)'s cladribine tablets, was rejected for a second time by the committee on cancer safety issues.